AstraZeneca plc (ADR) (NYSE:AZN) has finally unveiled its wonder-drug Lynparza or Olaparib that works in curing men from the vagaries of prostate cancer. The company has conducted several tests and clinical trials, following which it has revealed its drug that can cure ovarian or prostate cancer in females and males respectively.
Justice To Prior Pfizer-Takeover Bid
This news has boosted the performance of the British company’s stocks; share price surged. Further, this is great news for the cancer drug researcher unit’s drug pipeline for treating deadly disease – cancer. Besides, the latest achievement has been an apt defensive measure for the company’s $118 million takeover bid for Pfizer Inc. (NYSE:PFE) in 2014. Truly, the takeover bid looks justified, seeing the range of development that the company has shown.
AZN’s flagship drug Olaparib promises to be a potential seller of at least $2 billion each year. The current Phase III studies encompass gastric, breast, pancreatic and ovarian cancers. The drug has a promising market paved for it when it gains the center-stage.
How The Drug Functions?
Olaparib blocks the enzyme that works towards cell repair. Hence, it has been approved for usage on womenfolk who have hereditary instances of BRCA gene mutations and ovarian cancer. Further, men with genomic faults or prostate tumors may benefit from the consumption of this innovative drug.
Investigator Comments In Favor Of Olaparib
Investigator of Britain’s Institute of Cancer Research (BICR) Johann de Bono said that the latest research work opens up avenues for precise and useful advanced treatment against prostate cancer. This is duly guided by genomic testing and based on molecular characteristics of myriad of tumors that evolve in patients.
What Does Reports Suggest?
Statistical report by de Bono suggested that out of 49 men, 16 have developed treatment-resistant variants of prostate cancer; eventually, the minority of 16 patients even responded when acted upon by Olaparib. Among the men, 14 had detectable complicacies of DNA repair mutations. There are anticipations that in the consequent trials, the response rate would be far higher.